Published by MyelinWatch:
Petratos / DITPA research · NeuOrphan presents Dioprotectome as a candidate for MS that is still at the laboratory-and-animal research stage. The available sources do not establish that Dioprotectome and DITPA are the same molecule. Separately, Monash studies DITPA, a compound related to thyroid hormones, for a possible role in myelin repair.
NeuOrphan presents Dioprotectome as a candidate for MS that is still at the laboratory-and-animal research stage. The available sources do not establish that Dioprotectome and DITPA are the same molecule. Separately, Monash studies DITPA, a compound related to thyroid hormones, for a possible role in myelin repair.
No clinical study in MS is established
Research so far is in laboratory cells or animal models.
The Monash programme listing says this research is active through March 2028. Findings reported for DITPA are from laboratory and animal studies only. No established clinical study of DITPA in MS or proven benefit for people with MS is documented.
DITPA is not an available treatment for MS. The available sources do not establish a clinical study of DITPA for MS, so they do not show whether it benefits people with MS.
Steven Petratos's team reported that daily DITPA by mouth reduced neurological decline, helped myelin-making cells survive, reduced damage to myelin and nerve fibres, and improved related measurements in mice.
Source: Research Square / Monash University — research preprint ↗
